Category: Capital Markets

Maricann Enters Exclusivity Agreement to Bring Authentic Rare Dankness Cannabis Cup Award Winning Products to Canada

SHARE THIS POST TORONTO, Ontario, January 2, 2017 —Maricann Group Inc. (CSE:MARI, OTCQB: MRRCF, Frankfurt: 75M “Maricann” or the “Company”) announced today that it has entered into an exclusivity agreement (the “Exclusivity Agreement”) with Rare Dankness LLC (“RD”) to bring the world’s most sought after certified strains and cannabis products to Canada. Rare Dankness was founded in 2010 after many years of growing, collecting, preserving, and experimenting with many varieties of Cannabis. The Rare Dankness genetics bank spans three decades and represents what they believe to be the finest specimens of Cannabis strains in the world. Rare Dankness developed genetics do not simply replicate the “mothers”, but compliment the genetics by breeding with superior males, and breed specifically for certain cannabinoid and terpene profiles. Specializing in elite/rare genetics, Rare Dankness has created new and innovative genetics, including: Ghost Train Haze #1, Rug Burn OG, The OX, CBD OX (a 1:1 CBD strain), and Moonshine Haze. Rare Dankness is a multi winner of the High Times Cannabis Cup for their various strains, are listed first and third in the Legends of Hash #11 and have won over 80 awards worldwide. Rare Dankness is a Colorado based company with a separate European company for the world wide medical cannabis legal market. “As a globally recognized brand, with constantly increasing market awareness, our commitment to quality and the cannabis culture, make Rare...

Read More

Veritas Pharma Enters Binding Letter of Intent to Secure ACMPR License and Cannabis Growing Facility

SHARE THIS POST VANCOUVER, November 18, 2017- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”), an emerging-stage pharmaceutical and IP development company, is pleased to announce that it has signed a Binding Letter of Intent with 906474 Alberta Ltd. (“906474”)subject to regulatory authority to acquire 100% ownership of Sechelt Organic Marijuana Corp. (“SOM”), free and clear of all liens, charges and encumbrances in exchange for $800,000 payable in shares of Veritas (“Veritas Shares”) priced at the last trading day immediately preceding the Closing (the “Purchase Price”). Veritas is also issuing to 906474 Special Warrant Shares which would entitle 906474 to additional shares of Veritas equal to $800,000 less the current market price of the Veritas Shares times the market price on last trading day immediately following the 4 month holding period. SOM, currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada and, since July 4, 2014, has had an application with Health Canada to become a licensed producer under the ACMPR. Dr. Lui Franciosi, CEO, Veritas Pharma comments, “This is a win-win scenario for Veritas and its shareholders. We believe this transaction is both tactical and value driven. Further and most importantly, it is representative of the steps we will take to secure and maximize our position along the medical marijuana supply chain. We are making great strides...

Read More

InMed to Present at Cannabis-Based Science & Medicine Conference

SHARE THIS POST Vancouver, BC – November 16, 2017 – InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at the Biopharma Forum on ‘Cannabis-Based Science & Medicine’ conference on Thursday, November 30th and Friday, December 1st, 2017 in Denver, CO. Dr. Sazzad Hossain, InMed’s Chief Scientific Officer, will be presenting a lecture entitled “Epidermolysis to Glaucoma – Identifying Pathology Candidates for Cannabis-Based Treatments.” This presentation will highlight InMed’s internal process of identifying disease targets for treatment with therapeutic cannabinoid compounds, developing tissue-specific delivery formulations, and innovative approaches to addressing regulatory challenges with cannabinoid-based therapies. More information on this conference, organized by CBI – a division of UBM, is available at: http://www.cbinet.com/conference/pc17091 About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com. Contact: InMed Pharmaceuticals Inc. Chris Bogart Investor Relations T: 604.669.7207 E: chris@inmedpharma.com TroyFlowers Author description...

Read More

Veritas and Cannevert Hires the Essèntium Group as Their Agent in Puerto Rico USA

SHARE THIS POST November 14, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces that the Company through its research arm, Cannevert Therapeutics Ltd. (“CTL”) has hired the Essèntium Group LLC, a leading consulting firm, as their agent to provide advice on clinical investigators and licensed medical cannabis producers to assist in the implementation of a clinical trial of a cannabis strain in the US territory of Puerto Rico. Veritas CEO, Dr. Lui Franciosi stated, “We are pleased to have this group help us with our mission of establishing the therapeutic potential of Cannevert’s cannabis strains. Although the people of Puerto Rico have endured a significant weather event this past September, they have demonstrated a will to immediately rebuild for the better. Over the years, this territory has been an active player within pharmaceutical industry with an abundance of expertise and infrastructure that Veritas will take advantage.” Dr. Franciosi goes on to say, “They have numerous licensed producers of medical cannabis with whole new varieties that are of great interest to us.” Puerto Rico is one of the world’s best known pharmaceutical production and development centers with a growing biotech presence. Most of the biggest pharmaceutical companies have used this US territory as a manufacturing or outsourcing base due to its established infrastructure, highly skilled labour force, popular tax...

Read More

Veritas Pharma Initiates Cancer Research with Dr. Dmitri Petchkovski

SHARE THIS POST VANCOUVER, British Columbia, Nov. 14, 2017 — Veritas Pharma Inc. (CSE:VRT); (OTC:VRTHF); and (Frankfurt:2VP), (“Veritas” or the “Company”) announces that it has initiated a cancer research project to assess the effects of several human cancer cell lines against select cannabis strains, along with standard clinical chemotherapeutic drugs for comparison. The Company has engaged Dr. Dmitri Petchkovski of Fibroblast Consulting in Vancouver, Canada to specifically investigate lung, prostate, colon, breast, and melanoma cancer cell lines. Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”) will provide Dr. Petchkovski with the required strains and oversee the implementation of this project. Veritas CEO, Dr. Lui Franciosi stated, “We are fortunate to obtain Dr. Petchkovski’s expertise, who will now begin the important task of scientifically determining the potential anticancer properties of Cannevert’s cannabis strains. Cancer is a disease that has touched many people and we want to provide physicians and patients with the best possible scientific evidence when prescribing cannabis as a treatment.” Cancer is a disease that results from changes in a group of normal cells within the body where they begin to grow uncontrollably to the point that a lump known as a tumor forms. If left untreated, these tumors spread into the surrounding normal tissue or to other parts of the body. According to Canadian Cancer Statistics 2017, there is an estimated 206,200 new cases of cancer and 80,800...

Read More